Executive Summary: Key Legal and Evidentiary Issues

• Central issue was whether federal public health authorities owed a private law duty of care to an individual vaccine recipient (and his family) arising from approval, monitoring, and public promotion of the Pfizer-BioNTech COVID-19 vaccine.
• The court examined whether the statutory health-regulation framework, including the Food and Drugs Act, Interim Order and related legislation, creates duties to specific individuals or only to the Canadian public at large.
• A key evidentiary controversy concerned the appellant’s interpretation of clinical trial “Study 1” and “Study 2” data, and whether that data could plausibly support the pleaded allegation that the vaccine was only “minimally effective.”
• The appeal tested the limits of the intentional tort of misfeasance in public office, particularly the need for pleaded material facts showing deliberate unlawful conduct and subjective awareness (or wilful blindness) that harm to the plaintiff was likely.
• Residual policy considerations—indeterminate liability, and the risk of chilling government decision-making in managing pandemics—were decisive in negating any arguable novel duty of care, even if proximity could be assumed.
• Procedurally, the court addressed whether the claim, struck on a Rule 21 motion as having no reasonable prospect of success, should nonetheless survive via amendments or discovery, ultimately holding that the pleading’s defects were incurable and denying leave to amend.

Factual background and the Hartman family’s claim

The case arises from the death of 17-year-old Sean Hartman, who died on September 27, 2021, thirty-three days after receiving a Pfizer-BioNTech COVID-19 vaccine dose. His father, Daniel Hartman, brought an action under s. 61(1) of Ontario’s Family Law Act seeking damages for the loss arising from his son’s death, naming as defendants the Attorney General of Canada and the federal Minister of Health. The core allegation was that Sean’s death was caused by the vaccine and that federal authorities’ conduct in approving, monitoring, and promoting the vaccine was negligent, recklessly indifferent, or wilfully blind. The pleading also asserted misfeasance in public office. (Claims in deceit and fraud were initially pleaded but not pursued on appeal.) The factual foundation of the claim rested heavily on two datasets from the Pfizer-BioNTech Phase 3 clinical trial. “Study 1” encompassed the data considered at the time of the initial authorization in December 2020—data also reflected in a Health Canada Regulatory Decision Summary. “Study 2” comprised six-month follow-up results released by the manufacturer in April 2021 and summarized in a press release and later scientific publication. The appellant argued that these datasets, properly interpreted, showed minimal vaccine efficacy but significant risks of adverse and serious adverse events.

Public health context and the federal regulatory framework

The court set the case against the backdrop of the COVID-19 pandemic. By early 2020, COVID-19 had spread worldwide, causing hundreds of thousands of cases and tens of thousands of deaths in Canada alone. Governments responded with non-pharmaceutical measures such as social distancing, testing, and closures, while prioritizing rapid development and approval of safe and effective vaccines. Under the ordinary framework, the Minister of Health reviews new drugs under the Food and Drug Regulations (New Drugs Regulation), which require extensive data on safety and efficacy. Section 30.1 of the Food and Drugs Act allows the Minister to issue interim orders when immediate action is required to address significant risks to health. Relying on that power, the Minister issued the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, which created a special, more flexible pathway for COVID-19 drugs. While it modified administrative processes (including “rolling” submissions of data), the Interim Order maintained substantively similar evidentiary standards for demonstrating vaccine quality, safety, and effectiveness. Section 5 of the Interim Order obliged the Minister to issue an authorization where three conditions were satisfied: the application met specified informational requirements, the applicant provided any additional requested information, and the Minister had “sufficient evidence” to conclude that benefits outweighed risks, taking into account uncertainties and the urgent public-health need.

Clinical trial data and the federal approval decision

Pfizer-BioNTech applied for authorization on October 9, 2020. Health Canada reviewed the data from a large Phase 3 randomized, placebo-controlled trial involving roughly 44,000 participants. According to the Regulatory Decision Summary, by December 2020 the vaccine demonstrated about 95% efficacy in preventing symptomatic COVID-19: the vaccinated group had a 95% lower risk of contracting COVID-19 than the placebo group. The vaccine was also well tolerated across demographic groups; common side effects were localized pain, fatigue, headache, muscle aches, chills, joint pain, and fever, and no life-threatening adverse events or deaths were attributed to the vaccine in the trial. On that basis, and having regard to the urgent need to address the pandemic, the Minister concluded that benefits outweighed risks and authorized the vaccine for those 16 and older under the Interim Order. The Decision Summary flagged as a limitation the absence of long-term safety and efficacy data, but Health Canada planned ongoing monitoring as more evidence emerged.

Updated six-month data and the appellant’s interpretation

“Study 2” contained six-month follow-up data. By April 2021, vaccine efficacy remained above 90%, with a reported 91.3% efficacy against infection and about 95.3% efficacy against severe COVID-19. The updated data continued to show no significant new safety concerns: overall deaths were similar between vaccine and placebo arms, and no deaths were considered vaccine-related by trial investigators. The appellant, however, pleaded that the difference in infection rates between groups was only “3.6%,” calculated as the difference between a roughly 4.0% infection rate in the placebo group and a 0.4% infection rate in the vaccinated group. He argued that this small absolute difference, when compared with higher rates of reported adverse events in the vaccine group, showed that the vaccine’s benefits were marginal and its risks high. The Court of Appeal rejected this framing. It emphasized that the correct measure of efficacy is relative risk reduction: participants receiving placebo were about ten times more likely to contract COVID-19 than vaccinated participants, consistent with a 91.3% efficacy rate. The same data, properly understood, showed that placebo recipients were roughly thirty times more likely to develop severe COVID-19 than vaccinated participants. On the face of the pleaded trial data, the vaccine was highly effective, not minimally so.

Alleged negligent statements and duties of care

In addition to challenging the approval and monitoring process, the claim attacked a series of public communications (the “Impugned Statements”) made by Health Canada, the Minister, the Prime Minister, the Public Health Agency of Canada, and the Chief Public Health Officer. These statements broadly asserted that vaccines approved by Health Canada were safe and effective, urged “everyone” or “all people in Canada” to get vaccinated, and promoted vaccination as the best path to ending the pandemic, reducing infection rates, and relieving pressure on the health-care system. The appellant argued that, based on the clinical trial data available at the time, these statements were false and misleading. He said federal authorities thereby breached: (1) a duty of care when exercising operational functions in regulating the vaccine; (2) a duty of care when making representations about safety and efficacy; and (3) a duty to warn of elevated myocarditis risks in individuals under 40, especially adolescent males. He further alleged that Sean relied on these assurances and that, but for them, he would not have been vaccinated.

The motion to strike and the first-instance ruling

The defendants brought a Rule 21.01(1)(b) motion in the Ontario Superior Court of Justice to strike the entire claim on the basis that it disclosed no reasonable cause of action and had no reasonable prospect of success, even with the plaintiff’s proposed amendments. The motion judge accepted that Sean’s death was a profound loss but concluded that both the negligence and misfeasance claims were bound to fail. In negligence, she held that the statutory scheme created duties toward the public at large, not toward individual vaccine recipients, and that there were no pleaded specific interactions establishing proximity between Sean and federal decision-makers. The challenged conduct—regulating and promoting a national vaccination program during a pandemic—was characterized as core policy, immune from negligence liability, and any prima facie duty of care would in any event be negated by residual policy considerations such as indeterminate liability and the chilling effect on governmental responses to public-health emergencies. In misfeasance, the judge found that the pleading lacked material facts showing deliberate unlawful conduct or subjective awareness that harm to Sean was likely. Conclusory allegations of reckless indifference or wilful blindness without particularized facts did not meet the stringent pleading standard for an intentional tort requiring bad faith. She refused leave to amend, finding that the proposed additions merely repeated or elaborated on the same factual theory and could not cure the fundamental legal defects.

The appeal and applicable legal tests

On appeal, Mr. Hartman argued that the motion judge misapplied the high “plain and obvious” threshold for striking pleadings, failed to read the claim generously, wrongly classified the impugned conduct as core policy, erred in finding no arguable duty of care, misconstrued the pleading of misfeasance, and unreasonably withheld leave to amend. The Court of Appeal reviewed the Rule 21 decision for correctness and approached the refusal to permit amendments with deference, intervening only if there was a palpable and overriding error. The governing principles on motions to strike were restated: facts pleaded (and properly incorporated documents) are assumed true unless manifestly incapable of proof; bare legal conclusions are not; and arguable novel claims should proceed where there is a reasonable prospect of success, subject to the possibility of amendment.

Public authority negligence and the Anns/Cooper framework

In addressing negligence, the Court of Appeal applied the Anns/Cooper two-stage duty of care analysis for public authorities. It first considered whether the case fit within an established duty category; finding no direct analogy, it turned to whether a new duty should be recognized. On proximity, the court looked both to the statutory framework and any specific interactions. It reviewed the Department of Health Act and the Public Health Agency of Canada Act, emphasizing provisions that charge the Minister and PHAC with promoting and preserving “the health of the people of Canada,” protecting against risks to health and the spread of disease, and supporting national preparedness for public-health threats. These were expressly framed as obligations to the population as a whole, not to defined individuals or subgroups. The court relied on prior appellate authorities—most notably Williams v. Ontario and Abarquez v. Ontario (SARS-related claims) and the Federal Court decision in Adam, Abudu v. Ledesma-Cadhit (H1N1 vaccination)—to underscore that emergency public-health responses inherently involve trade-offs among competing interests and cannot ground private duties to particular persons that would conflict with the overarching duty to protect the public. As to specific interactions, the court held that the impugned public statements, by their own wording, were directed to “everyone” or “all people in Canada.” They were classic mass-communication policy messaging, not individualized advice or representations to Sean or any defined, narrow class. No special relationship sufficient to create proximity was pleaded. Even if, contrary to its analysis, a prima facie duty could be inferred, the court held that residual policy considerations would still negate it. Recognizing such a duty would expose governments to indeterminate liability to an unlimited class of vaccine recipients and unduly inhibit their ability to make necessary, sometimes unpopular, choices in managing pandemics. Accordingly, it was plain and obvious that no private law duty of care arose and the negligence claim was doomed to fail.

Misfeasance in public office: unlawful conduct and knowledge of likely harm

The court then turned to the misfeasance claim. It reaffirmed that misfeasance in public office requires: (1) deliberate unlawful conduct by a public officer acting in their official capacity, and (2) actual knowledge (or established recklessness/wilful blindness) that the conduct is unlawful and likely to harm the plaintiff. The tort is targeted at bad-faith exercises of public power that disregard the rule of law, not at negligence or policy errors. Because it is an intentional tort implicating allegations of bad faith or dishonesty, Rule 25.06(8) requires “full particulars,” and prior case law demands a “stringent standard of particularity.” Against this standard, the appellate court agreed that the pleading was deficient. First, the allegation that regulators and the Minister engaged in “unlawful conduct” by approving, maintaining, or promoting a supposedly “minimally effective” vaccine was unsupported by material facts. Once the clinical trial data is properly read—as showing high efficacy and no vaccine-related deaths or serious new safety concerns—the pleaded facts actually cut against any inference of unlawfulness. Second, and even more fundamentally, the claim did not plead facts suggesting that federal officials knew, or were wilfully blind to, an elevated risk of serious harm (such as myocarditis in adolescent males) that outweighed the vaccine’s benefits at the time of their decisions or statements. Nor did it allege any individualized awareness of risk to Sean specifically or to a narrow, well-defined population cohort he belonged to. The result was a series of bald assertions of knowledge and bad faith untethered to particularized evidentiary facts. Such allegations could not sustain an intentional tort of misfeasance and therefore were bound to fail on a motion to strike.

Refusal of leave to amend and the limits of discovery-driven pleading

On the amendment issue, the Court of Appeal accepted that, as a general rule, even flawed pleadings should be given an opportunity to be cured unless it is clear that no amendment could bridge the legal gap. Here, however, it endorsed the motion judge’s conclusion that the proposed amendments added detail but did not address the core problems: the absence of an arguable duty of care in negligence and the lack of factual particulars necessary to support misfeasance. The appellant’s suggestion that discovery might uncover supporting facts was rejected. The court emphasized that litigation cannot be used as a “fishing expedition.” Plaintiffs must plead concrete facts at the outset, especially where the key documents—such as the clinical trial publications and regulatory summaries—are already publicly available and relied upon in the pleading itself. Since the defects were legal and structural rather than merely technical, this was one of the “clearest of cases” in which denying leave to amend was appropriate.

Outcome and monetary consequences

In the end, the Ontario Court of Appeal dismissed Daniel Hartman’s appeal and affirmed the order striking out his action in its entirety, without leave to amend. It expressly recognized the tragedy of Sean Hartman’s death but held that, as a matter of law, the pleaded causes of action could not succeed against federal public health authorities on the facts and legal framework described. The respondents—the Attorney General of Canada and the Minister of Health—were therefore the successful parties. Both at first instance and on appeal, the courts declined to award costs, and no damages were ever assessed or granted. As a result, while the federal defendants prevailed completely, no monetary award, costs, or damages were ordered in their favour and the total amount granted was effectively zero, with no quantifiable sum determined.